Article

A new rating scale for Alzheimer's disease.

American Journal of Psychiatry (Impact Factor: 13.56). 12/1984; 141(11):1356-64.
Source: PubMed

ABSTRACT A new rating instrument, the Alzheimer's Disease Assessment Scale, was designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic of persons with Alzheimer's disease. Item descriptions, administration procedures, and scoring are outlined. Twenty-seven subjects with Alzheimer's disease and 28 normal elderly subjects were rated on 40 items. Twenty-one items with significant intraclass correlation coefficients for interrater reliability (range, .650-.989) and significant Spearman rank-order correlation coefficients for test-retest reliability (range, .514-1) constitute the final scale. Subjects with Alzheimer's disease had significantly more cognitive and noncognitive dysfunction than the normal elderly subjects.

Download full-text

Full-text

Available from: Richard C Mohs, Aug 20, 2014
9 Followers
 · 
466 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We studied the association of SORL1 single-nucleotide polymorphisms genotypes with measures of pathology in patients with probable Alzheimer's disease (AD) using an endophenotype approach. We included (1) 133 patients from the German Dementia Competence Network (71 ± 8 years; 50% females; Mini Mental State Examination [MMSE], 24 ± 3); (2) 83 patients from the Alzheimer's Disease Neuroimaging Initiative (75 ± 8 years; 45% females; MMSE, 24 ± 2); and (3) 452 patients from the Amsterdam Dementia Cohort 66 ± 8 years; 47% females; MMSE, 20 ± 5). As endophenotype markers we used cognitive tests, cerebrospinal fluid (CSF) biomarkers amyloid-beta, total tau (tau), tau phosphorylated at threonine 181, and hippocampal atrophy. We measured 19 SORL1 SNP alleles. Genotype-endophenotype associations were determined by linear regression analyses. There was an association between rs2070045-G allele and increased CSF-tau and more hippocampal atrophy. Additionally, haplotype-based analyses revealed an association between haplotype rs11218340-A/rs3824966-G/rs3824968-A and higher CSF-tau and CSF-tau phosphorylated at threonine 181. In conclusion, we found that SORL1 SNP rs2070045-G allele was related to CSF-tau and hippocampal atrophy, 2 endophenotype markers of AD, suggesting that SORL1 may be implicated in the downstream pathology in AD. Copyright © 2015 Elsevier Inc. All rights reserved.
    Neurobiology of Aging 12/2014; 36(3). DOI:10.1016/j.neurobiolaging.2014.12.007 · 4.85 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction The diagnostic approach for Alzheimer's disease is based on the presence of cerebral atrophy combined with the score of the mini-examination of the mental state. In this context, this study was conducted to assess the correlation between imaging and neuropsychological testing for cases of early-onset and late-onset Alzheimer's disease. Aim of the study Analysis of the clinical and paraclinical aspects of Moroccan cases with Alzheimer's disease. Methods Seventeen sporadic cases and 8 family cases were seen at the memory clinic of the Neurology Department of the University of Casablanca Ibn Rochd Hospital. A family history was obtained through a clinical interview of the patient and a yes or no self-reporting questionnaire from the guardian or other family member. The disease was considered familial if at least one additional first degree relative suffered from early-onset AD-type dementia. All patients underwent standard somatic neurological examination, cognitive function assessment, brain imaging and laboratory tests. Written consent was obtained from the patients and their guardians prior to the study. Results In our study of 25 individuals, the observed mean age of AD patients was 64.52 ± 9.30 and we observed a slight female predominance (56% versus 44%). In addition, we found a prevalence of AD of approximately 20%, increasing with age, in the population below 60 years of age. Approximately half of our patients (48%) had a score lower than 10 and were affected by severe insanity, while 28% were affected by moderate severe insanity and 24% were light to moderately insane. Twenty-five patients underwent neuroimaging, 18 of whom were assessed by MRI, while 7 were assessed by CT. All patients had hippocampal atrophy, which progressed to affect others brain regions. The blood tests showed no abnormalities in the 25 enrolled AD cases. Discussion Age is undoubtedly the main risk factor for AD; this is also the true for our cases where advanced age was responsible for the exponential increase of the disease's frequency; it reached a peak in the age group of 60–69 years. The AD diagnosis approach is based on the presence of cerebral atrophy combined with the score of the mini-examination of the mental state (MMSE). In our study, in addition to the MMSE, depending on the level of education, the clinician used other tests that do not necessarily require a level of education such as the BEC96, visual short-term or digital memory assessment, work memory assessment, language assessment test (DO80) and apraxia. Neuropsychological examination of the cases with a score of less than 10 showed severe cognitive impairment. The cases presented memory and language impairments, aphasia, visual spatial disorientation, decreased autonomy, executive dysfunction and praxis deficits, all major causes of severe dementia. Neuroimaging revealed hippocampal and cortical atrophy. Correlated with the other studies that aimed to establish links between brain alterations and neuropsychological disorders, we can conclude that a higher level of atrophy reflects a decrease in neuropsychological performance.
    L Encéphale 12/2014; DOI:10.1016/j.encep.2014.06.006 · 0.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer’s disease (AD) is a neurodegenerative disorder of the brain, inducing progressive severe presenile and senile cognitive decline, resulting in vegetative stage eventually. From the etiological point of view the main causative factor, remains unknown, in spite of the steady augmentation of the research efforts. Golgi staining revealed the substantial alterations of the dendritic branches and the tremendous loss of spines even in the initial stages of the disease. Electron microscopy reveals morphological changes of the mitochondria in neurons and astrocytes associated with fragmentation of cisternae of Golgi complex and pathological alteration of the dendritic spines, even in areas of the brain, which demonstrate minimal tau pathology and few amyloid β deposits. It is attempted to describe the ultrastructural alterations of the cerebellar cortex in early cases of AD, focusing the study mostly on mitochondria, Golgi apparatus, dendritic branches, dendritic spines and synapses in the cerebellar hemispheres and the vermis. Mitochondria demonstrated an impressive polymorphism in the soma, the axonal and dendritic profiles of Purkinje cells, the climbing fibers, the mossy fibers and the synapses. Electron microscopy revealed also marked fragmentation of cisternae of Golgi complex in large number of Purkinje cells, granule and stellate cells in the vermis and the cerebellar hemispheres. The fragmentation of the Golgi complex and the poverty in vesicles in cis- and trans-Golgi network in the soma of Purkinje cells in Alzheimer’s brains coincide with the synaptic loss, the shortage of the dendritic arborization and the pathological alterations of the spines. Numerous spines included large multivesicular bodies, altered spine apparatus, and unusual mitochondria. Giant elongated spines were seen in a substantial number of Purkinje cells. In many presynaptic terminals of parallel and mossy fibers, electron microscopy revealed a dramatic loss of the synaptic vesicles associated with marked polymorphism. On the basis of the mitochondrial and Golgi complex pathology, new therapeutic strategies protecting those organelles might be proposed for the treatment of early cases of AD.
    Frontiers in Clinical Drug Research - Alzheimer Disorders,, 1st edited by Atta-ur-Rahman, 12/2014: chapter 1: pages 3-27; Bentham Science Publishers., ISBN: 978-1-60805-871-6